Format

Send to

Choose Destination
Cerebrovasc Dis. 2005;20(2):101-7. Epub 2005 Jun 21.

Neurotransplantation of fetal porcine cells in patients with basal ganglia infarcts: a preliminary safety and feasibility study.

Author information

1
Department of Neurology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Mass. 02215, USA.

Abstract

BACKGROUND:

Cell transplantation is safe in animal models and enhances recovery from stroke in rats.

METHODS:

We studied the safety and feasibility of fetal porcine transplantation in 5 patients with basal ganglia infarcts and stable neurological deficits. To prevent rejection, cells were pretreated with an anti-MHC1 antibody and no immunosuppressive drugs were given to the patients.

RESULTS:

The first 3 patients had no adverse cell, procedure, or imaging-defined effects. The fourth patient had temporary worsening of motor deficits 3 weeks after transplantation, and the fifth patient developed seizures 1 week after transplantation. MRI in both patients demonstrated areas of enhancement remote from the transplant site, which resolved on subsequent imaging. Two patients showed improvement in speech, language, and/or motor impairments over several months and persisted at 4 years. The study was terminated by the FDA after the inclusion of 5 patients.

CONCLUSION:

This is the first report on the transplantation of nontumor cells in ischemic stroke patients.

PMID:
15976503
DOI:
10.1159/000086518
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for S. Karger AG, Basel, Switzerland
Loading ...
Support Center